Verisk Analytics (NASDAQ:VRSK) Price Target Lowered to $262.00 at Evercore ISI
Verisk Analytics (NASDAQ:VRSK – Get Free Report) had its target price lowered by stock analysts at Evercore ISI from $292.00 to $262.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has an "in-line" rating on the business services provider’s stock. Evercore ISI’s price objective suggests a potential upside of 7.62%…
This article is available to Insider Pro subscribers only.Sign in or register to be an Insider Pro and access ALL LOCKED articles.
What Can Public Employers Do About Skyrocketing Health-Care Costs?
INSURANCE COMMISSIONER TAKES ACTION TO PROTECT WISCONSIN CONSUMERS ISSUING A FINAL DECISION AGAINST CONTRACTOR ACTING AS PUBLIC ADJUSTER
Advisor News
- Addressing the ‘menopause tax:’ A guide for advisors with female clients
- Alternative investments in 401(k)s: What advisors must know
- The modern advisor: Merging income, insurance, and investments
- Financial shocks, caregiving gaps and inflation pressures persist
- Americans unprepared for increased longevity
More Advisor NewsAnnuity News
- Globe Life Inc. (NYSE: GL) Making Surprising Moves in Monday Session
- Aspida Life and WealthVest Offer a Powerful New Guaranteed Income Product with the WealthLock® Income Builder
- Lack of digital tools drives wedge between insurers, advisors
- LIMRA: Annuity sales notch 10th consecutive $100B+ quarter
- AIG to sell remaining shares in Corebridge Financial
More Annuity NewsHealth/Employee Benefits News
- We can't afford to let Democrats lead health care 'reform' | Opinion
- Expanding Medicaid coverage lowered death rates for young adults with kidney failure
- GLP-1s: Rewriting the relationship between pharmacy benefits and stop-loss
- Studies from Denise Wolff et al Have Provided New Data on Atopic Dermatitis (AMCP Market Insights: Beyond skin deep on the role of managed care in moderate to severe atopic dermatitis): Skin Diseases and Conditions – Atopic Dermatitis
- New Clinical Trials and Studies Findings from RAND Corporation Described (Benefit design and consumer information: results from a randomized trial): Clinical Research – Clinical Trials and Studies
More Health/Employee Benefits NewsLife Insurance News
- 3 ways AI can help close the gap for women’s insurance coverage
- Best’s Market Segment Report: AM Best Revises Outlook on Italy’s Life Insurance Segment to Stable From Negative
- Globe Life Inc. (NYSE: GL) Making Surprising Moves in Monday Session
- Dan Scholz to receive NAIFA’s Terry Headley Lifetime Defender Award
- Best’s Special Report: US Property/Casualty and Health Insurers Exceed Cost of Capital; Life Insurers Narrowly Miss
More Life Insurance News